Published by Josh White on 9th December 2025
(Sharecast News) - Scancell reported further positive clinical data for its DNA cancer immunotherapy iSCIB1+, on Tuesday, saying updated phase two results supported its selection for late-stage development in first-line advanced melanoma and reinforce the target patient population.
URL: http://www.digitallook.com/dl/news/story/35550376/...